Nikeshan Jeyakumar

Employment

• UCLA Health

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (6)

• Improved outcomes with TKI maintenance after brexucabtagene autoleucel in Philadelphia chromosome ALL
  Blood Advances 2026 DOI: 10.1182/bloodadvances.2026020707
  +Save
• Real-world toxicity of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia
  Blood Immunology & Cellular Therapy 2026 DOI: 10.1016/j.bict.2025.100028
  +Save
• CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia
  Blood Advances 2026 DOI: 10.1182/bloodadvances.2025017526
  +Save
• Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL
  Ibrahim Taha Aldoss, Gregory W. Roloff, Rawan G. Faramand +60 more
  Blood Advances 2024 DOI: 10.1182/bloodadvances.2024013747
  +Save
• A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia
  Blood 2024 DOI: 10.1182/blood.2024024952
  +Save
• The Terrible Triad of Checkpoint Inhibition: A Case Report of Myasthenia Gravis, Myocarditis, and Myositis Induced by Cemiplimab in a Patient with Metastatic Cutaneous Squamous Cell Carcinoma
  Case Reports in Immunology 2020 DOI: 10.1155/2020/5126717
  +Save